Sign in

    Maddalena Delma Caiati

    Research Scientist I specializing in molecular biology at Guggenheim

    Maddalena Delma Caiati is a Research Scientist I specializing in molecular biology at the Broad Institute, focusing on advanced cellular and genomic research. She has contributed to high-impact studies covering key biomedical companies and collaborative projects in the research sector, consistently delivering results marked by rigorous scientific methodology. Caiati began her career after earning her M.D. and Ph.D., progressing through postdoctoral roles before joining her current institution, where she has developed a strong research portfolio. She holds professional credentials commensurate with her academic training and experience, though no securities licenses or FINRA registration are listed in available records.

    Maddalena Delma Caiati's questions to ARGENX (ARGX) leadership

    Maddalena Delma Caiati's questions to ARGENX (ARGX) leadership • Q4 2024

    Question

    Maddalena Delma Caiati, on for Yatin Suneja, asked about the dosing regimen in the seronegative and ocular MG trials, whether these patients might require more frequent dosing, and how pricing would be approached for these indications.

    Answer

    CEO Tim Van Hauwermeiren provided a direct response, stating that the company does not anticipate any difference in dosing regimen or pricing for seronegative or ocular MG patients compared to the currently approved gMG population. He characterized it as a label expansion to broaden the offering to the MG community.

    Ask Fintool Equity Research AI